ACPE and Nitro

In suspected acute cardiogenic pulmonary edema (ACPE), a lack of improvement after several nitroglycerin doses alone is not a strong reason to discontinue treatment.

A practical approach is to finish the standing order unless there is a clear reason to withhold the medication. Nitroglycerin works by reducing preload (and at higher doses, afterload), but clinical improvement, especially in lung sounds, may not be immediate, and auscultation findings often lag behind actual physiologic changes.

More importantly, your decision-making should focus on overall clinical status rather than lung sounds, which are among the least reliable indicators of improvement. Instead, prioritize work of breathing (WOB), SpO₂, end-tidal CO2, and systolic blood pressure (SBP). If the patient remains hypertensive or normotensive, continues to have respiratory distress, and has no contraindications, it is reasonable to continue treatment. Conversely, nitro should be held or discontinued if SBP drops, the patient clinically deteriorates, or another contraindication develops.

It’s also important to recognize that nitroglycerin is just one part of management, and lack of response should prompt consideration of other treatment modalities. Early use of CPAP is highly effective in improving oxygenation and reducing work of breathing. Oxygen therapy should be considered.

Overall, if the patient is tolerating nitroglycerin and still shows signs consistent with ACPE, it is appropriate to continue (or complete) the standing order rather than stopping early based solely on unchanged lung sounds or subjective dyspnea.